medigraphic.com
ISSN 1561-302X (Print)

2014, Number 4

<< Back Next >>

Rev cubana med 2014; 53 (4)

Long-term mortality and follow-up loss of patients on antiretroviral therapy

Martínez FL, Corral MA, Serrano D, Furtado ML, Díaz THM, Machado ZLY, Barzaga TM

Language: Spanish
References: 60
Page: 373-391
PDF size: 399.05 Kb.


ABSTRACT

Introduction: long-term results of combination antiretroviral therapy (cART) in Africa have been poorly informed.
Objective: To evaluate the effectiveness of TARVC through 2 factors: mortality and follow-up loss.
Methods: A descriptive, retrospective, longitudinal study was conducted in 1000 adults who began cART in 2004 and were followed until 2009 at "Esperança" Hospital in Luanda.
Results: The CD4 + count mean baseline of T lymphocytes was 147.1 cells/mm3. 46 % presented with clinical stage III or IV according to World Health Organization standards. The average age was 34.6 years. During 60 000 person-months followup (mean 34 months), 335 patients died, 153 lost follow up and adherence to treatment after 5 years was 51.2 %. The gross mortality rate was 7.9 (95 % CI 5.6 to 8.3) 100 person-years. A significantly shorter survival mean was detected in women (39.1 months vs. 42), in those with lymphocytes CD4 + count baseline below 200 cells/mm3 (27.3 months vs. 32.4), in those classified in advanced stages according to WHO standards (25.6 months vs. 31.7) and in those reaching both clinical and immunological criteria to start therapy (30.4 months vs. 33.7 immunological only).
Conclusions: A good long-term adherence to treatment and clinical outcomes were observed. The relatively high mortality after 5 years presents a major challenge for better cART results and suggests the need to strengthen strategies to promote treatment adherence.


REFERENCES

  1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antirretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-29.

  2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352(9142):1725-30.

  3. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. WHO Library Cataloguing-in-Publication Data. [citado 8 Ag 2012]. Disponible en: http://www.who.int/hiv/pub/progressreports/update2014-executive-summary/en/

  4. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, Danel C, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antirretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther. 2003;8(5):385-93.

  5. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a communitybased HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96(4):315-20.

  6. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, et al. Long-term benefits of highly active antirretroviral therapy in Senegalese HIV-1- infected adults. J Acquir Immune Defic Syndr. 2005;38(1):14-7.

  7. Boileau C, Nguyen VK, Sylla M, Machouf N, Chamberland A, Traore HA, et al. Low prevalence of detectable HIV plasma viremia in patients treated with antirretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr. 2008;48(4):476-84.

  8. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antirretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367(9519):1335-42.

  9. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antirretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45(3):304-10.

  10. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19(18):2109-16.

  11. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antirretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20(12):1605-12.

  12. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIVinfected patients with very advanced immunodeficiency commencing antirretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006;6:59.

  13. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antirretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43(6):770-6.

  14. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antirretroviral service in South Africa: implications for programme design. AIDS. 2005;19(18):2141-8.

  15. Libamba E, Makombe S, Mhango E, de Ascurra Teck O, Limbambala E, Schouten EJ, et al. Supervision, monitoring and evaluation of nationwide scale-up of antirretroviral therapy in Malawi. Bull World Health Organ. 2006;84(4):320-6.

  16. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scaleup of antirretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296(7):782-93.

  17. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20(1):41-8.

  18. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, Van Rie A. Long term outcomes of antirretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc. 2009;12:38.

  19. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antirretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817-24.

  20. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, et al. Public-health and individual approaches to antirretroviral therapy: township South Africa and Switzerland compared. PLoS Med. 2008;5(7):e148.

  21. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antirretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887-95.

  22. Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, et al. Mortality of HIV-infected patients starting antirretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med. 2009;6(4):e1000066.

  23. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antirretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22(7):873-82. .

  24. Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP. Antirretroviral therapy outcomes in resource-limited settings for HIV-infected children < 5 years of age. Pediatrics. 2010;125(5):e1039-47.

  25. Negin J, van Lettow M, Semba M, Martiniuk A, Chan A, Cumming RG. Antiretroviral treatment outcomes among older adults in Zomba district, Malawi. PLoS One. 2011;6(10):e26546.

  26. Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, Fernandes KA, et al. Combination antirretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201.

  27. Schrooten W, Florence E, Dreezen C, Van Esbroeck M, Fransen K, Alonso A, et al. Five-year immunological outcome of highly active antirretroviral treatment in a clinical setting: results from a single HIV treatment centre. Int J STD AIDS. 2004;15(8):523-8.

  28. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antirretroviral treatment in Ethiopia: a retrospective cohort study. AIDS Res Ther. 2012;9(1):15. Epub 2012/05/23.

  29. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al. Survival of HIV-infected adolescents on antirretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One. 2011;6(4):e19261.

  30. Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, Jaye A, et al. Mortality and immunovirological outcomes on antirretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS. 2011;25(17):2167-75. Epub 2011/09/02.

  31. Davies NE, Karstaedt AS. Antirretroviral outcomes in South African prisoners: a retrospective cohort analysis. PLoS One. 2012;7(3):e33309.

  32. Ahonkhai AA, Noubary F, Munro A, Stark R, Wilke M, Freedberg KA, et al. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012;7(3):e32993.

  33. Chan AK, van Lettow M, Tenthani L, Kumwenda M, Gawa L, Kadzanja A, et al. Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study. PLoS One. 2011;6(5):e19789. Epub 2011/06/01.

  34. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, Labhardt ND, et al. Outcomes of antirretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr. 2012;59(2):e9-16.

  35. Okomo U, Togun T, Oko F, Peterson K, Townend J, Peterson I, et al. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antirretroviral therapy in a concentrated low prevalence setting in West Africa. BMC Pediatr. 2012;12:95.

  36. Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, et al. Treatment outcomes in HIV-infected adolescents attending a community-based antirretroviral therapy clinic in South Africa. BMC Infect Dis. 2012;12:21.

  37. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antirretroviral therapy in Uganda: randomised trial. BMJ. 2011;343:d6792.

  38. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antirretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health. 2009;14(1):36-43.

  39. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, Wood R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antirretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56(1):e1-8.

  40. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antirretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24(4):563-72.

  41. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, et al. Five-year outcomes of initial patients treated in Botswana's National Antirretroviral Treatment Program. AIDS. 2008;22(17):2303-11.

  42. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antirretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20(8):1181-9.

  43. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, et al. Temporal changes in programme outcomes among adult patients initiating antirretroviral therapy across South Africa, 2002-2007. AIDS. 2010;24(14):2263-70.

  44. Fox MP, Shearer K, Maskew M, Macleod W, Majuba P, Macphail P, et al. Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012;26(14):1823-8.

  45. Kipp W, Konde-Lule J, Saunders LD, Alibhai A, Houston S, Rubaale T, et al. Antirretroviral treatment for HIV in rural Uganda: two-year treatment outcomes of a prospective health centre/community-based and hospital-based cohort. PLoS One. 2012;7(7):e40902.

  46. Labhardt ND, Keiser O, Sello M, Lejone TI, Pfeiffer K, Davies MA, et al. Outcomes of antirretroviral treatment programmes in rural Lesotho: health centres and hospitals compared. J Int AIDS Soc. 2013;16:18616.

  47. Huet C, Ouedraogo A, Konate I, Traore I, Rouet F, Kabore A, et al. Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antirretroviral therapy in Africa. BMC Public Hhealth. 2011;11:700.

  48. Rosen S, Fox MP, Gill CJ. Patient retention in antirretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298.

  49. Musheke M, Bond V, Merten S. Individual and contextual factors influencing patient attrition from antirretroviral therapy care in an urban community of Lusaka, Zambia. J Int AIDS Soc. 2012;15 Suppl 1:1-50.

  50. Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antirretroviral therapy in a rural South African programme. PLoS One. 2011;6(5):e19201.

  51. Johansson KA, Robberstad B, Norheim OF. Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antirretroviral therapy. AIDS Res Ther. 2010;7(1):3. Epub 2010/02/26.

  52. Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, et al. Opportunistic infections occurring during highly active antirretroviral treatment. AIDS. 1998;12(14):1815-22. Epub 1998/10/29.

  53. French MA, Price P, Stone SF. Immune restoration disease after antirretroviral therapy. AIDS. 2004;18(12):1615-27.

  54. Carr A, Cooper DA. Adverse effects of antirretroviral therapy. Lancet. 2000;356(9239):1423-30.

  55. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antirretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21(18):2483-91.

  56. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, Anglaret X. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Hum Retroviruses. 2007;23(11):1338-47.

  57. Harling G, Orrell C, Wood R. Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res. 2007;7:80.

  58. SIDA INLS. Relatório sobre o Progresso do País para dar Seguimento aos Compromissos da Sessão Especial sobre VIH e SIDA da Assembleia Geral das Nações Unidas. 2010. [citado 9 jun 2010]. Disponible en: http://data.unaids.org/pub/Report/2010/angola_2010_country_progress_report_es.pdf

  59. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. [citado 6 nov 2014]. Disponible en: http://www.who.int/hiv/pub/vct/hivstaging/en/

  60. Fox MP, Rosen S. Patient retention in antirretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1-15.




2020     |     www.medigraphic.com